Valuation: Guided Therapeutics Inc

Market Cap 2.51Cr 2.21Cr 2.04Cr 1.91Cr 3.57Cr 236.59Cr 3.64Cr 24Cr 9.49Cr 116.71Cr 9.42Cr 9.22Cr 406.04Cr P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 2.8Cr 2.46Cr 2.27Cr 2.12Cr 3.98Cr 263.7Cr 4.06Cr 27Cr 11Cr 130.08Cr 11Cr 10Cr 452.57Cr EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 70 06/03/2023
Chief Tech/Sci/R&D Officer 70 02/12/2010
Director TitleAgeSince
Director/Board Member 70 01/12/2016
Director/Board Member 76 10/04/2006
Chairman 67 01/10/2013
Change 5-day change 1-year change 3-year change Capi.($)
+13.33%-.--% - - 2.51Cr
+4.87%+6.61%+21.72%-6.11% 18TCr
-0.33%-0.09%-23.18%+22.79% 14TCr
+5.53%+6.25%-4.36%-20.70% 13TCr
-2.50%-1.09%-57.30%-17.62% 6.61TCr
+3.12%+3.44%+18.21%-0.75% 5.16TCr
+0.16%-0.44%-27.02%-32.17% 4.34TCr
+3.92%+5.87%+11.89%+10.22% 3.72TCr
+3.35%+3.41%+6.45%+42.08% 3.62TCr
+1.82%+6.10%-9.86%-18.72% 2.95TCr
Average +3.40%-0.26%-7.05%-2.33% 8.03TCr
Weighted average by Cap. +2.78%-0.60%-4.90%-2.61%

Financials

2024 2025
Net sales 7T 6.16T 5.68T 5.32T 9.96T 7L 10.15T 68.31T 26.46T 3L 26.28T 25.71T 11.32L 8L 7L 6L 6L 10.91L 7.23Cr 11.12L 74.85L 28.99L 3.57Cr 28.8L 28.17L 12Cr
Net income -24.17L -21.28L -19.63L -18.36L -34.39L -23Cr -35.04L -2.36Cr -91.36L -11Cr -90.75L -88.78L -39Cr -31.96L -28.14L -25.95L -24.27L -45.48L -30Cr -46.33L -3.12Cr -1.21Cr -15Cr -1.2Cr -1.17Cr -52Cr
Net Debt 17.71L 15.59L 14.38L 13.45L 25.2L 17Cr 25.67L 1.73Cr 66.94L 8.23Cr 66.49L 65.05L 29Cr 28.76L 25.32L 23.35L 21.84L 40.93L 27Cr 41.69L 2.81Cr 1.09Cr 13Cr 1.08Cr 1.06Cr 47Cr
Logo Guided Therapeutics Inc
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
-